Nov 9, 2026, 5:52 PMPharmaceuticals
Ozempic, Zepbound and GLP-1 Drugs Linked to Possible Vision Loss Risk
Several studies link GLP-1 medicines, including Ozempic and Zepbound, to elevated NAION risk, a condition that can cause vision loss. Details are limited.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on November 9, 2026, that several medical studies found an elevated risk of nonarteritic anterior ischemic optic neuropathy, or NAION, among people taking GLP-1 medications. The headline identifies Ozempic, Zepbound and other drugs in the class and describes vision loss as a possible risk.
The available feed summary provided limited detail. It did not identify the studies, quantify incidence or absolute risk, establish causation, name manufacturers, or report regulatory action, financial effects or next steps.
Positives
- The article describes the association as a possible risk, not a confirmed causal finding.
- The available feed reports no regulatory action, product withdrawal or prescribing restriction.
- The limited summary discloses no financial or sales impact for any drugmaker.
Risks & concerns
- Several medical studies found elevated NAION risk among people taking GLP-1 medications.
- NAION can involve vision loss, making the reported association a potentially serious drug-class safety issue.
- Ozempic, Zepbound and other GLP-1 drugs are implicated by the headline, broadening concern beyond one product.
- No study names, incidence rates, sample sizes or follow-up steps were supplied, leaving the risk and next actions unquantified.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/ozempic-zepbound-and-other-glp-1-drugs-have-a-possible-risk-of-vision-loss-b3738f36?mod=mw_rss_topstories
Read full article

